Webinar: Translating ASCO 2026: What Matters Most for Managed Care

Major meetings such as ASCO present trial results that can change standards of care quickly. Some involve therapies already being prescribed off-label, and others are new drugs heading for FDA approval. Health plans need to judge which ones are becoming a new standard of care and are supported for coverage, so patients get timely access to treatments that improve outcomes.

Read: Translating ASCO 2026: What Matters Most for Managed Care

Selpercatinib is FDA approved only for advanced or metastatic RET fusion-positive non-small cell lung cancer. Based on the LIBRETTO-432 trial, NCCN guidelines now endorse its use after resection of earlier-stage disease, where it improved 24-month event-free survival to 91.5% from 61.1% in stage II–IIIA patients. It is another reason to test for biomarkers before early-stage treatment.

Read: Translating ASCO 2026: What Matters Most for Managed Care

Daraxonrasib is a first-in-class oral pan-RAS inhibitor. Unlike earlier KRAS drugs that target one mutation, it blocks the active form of mutant and normal KRAS, NRAS and HRAS. In the phase 3 RASolute-302 trial in previously treated metastatic pancreatic cancer, it doubled median overall survival compared with chemotherapy (13.2 vs 6.6 months). It is currently investigational.

Read: The End of “Undruggable?”: Why RASolute-302 May Mark the Beginning of the Pan-RAS Era